AUM $106.0MER 0.34%NAV $100.93Holdings 198Inception Dec 2014
Price Chart
Key Statistics
Previous Close
$103.48Day Range
$106.53$109.94
52-Week Range
$66.64$109.90
Avg Volume
9.3KDividend Yield
—Expense Ratio
0.34%AUM
$106.0MShares Outstanding
407.5KETF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 100.00% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 85.84% |
| United Kingdom | 4.89% |
| Switzerland | 3.10% |
| China | 1.93% |
| Denmark | 1.48% |
| Germany | 1.30% |
| Canada | 1.23% |
| Other | 0.21% |
Fund Information
- Issuer
- Virtus
- Category
- Healthcare
- Types
- Biotech
- Inception Date
- Dec 16, 2014
- Exchange
- NYSE_ARCA
- Description
- The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index, which tracks the performance of biotechnology companies with at least one drug therapy approved by the FDA.Effective February 27, this Fund's name changed from Virtus LifeSci Biotech Products ETF to Virtus Biotech ETF.
Similar ETFs
The Virtus Biotech ETF (BBP) is an exchange-traded fund issued by Virtus that launched on Dec 16, 2014. It currently manages $106.0M in assets under management. The fund charges an expense ratio of 0.34%. The fund holds 198 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 20.9% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | CRNX | Crinetics Pharmaceuticals Inc | 3.14% | 39,373 | $3.3M |
| 2 | OMER | Omeros Corp | 2.54% | 155,369 | $2.7M |
| 3 | VSTM | Verastem Inc | 2.08% | 331,013 | $2.2M |
| 4 | IOVA | Iovance Biotherapeutics Inc | 2.05% | 332,635 | $2.2M |
| 5 | ZLAB | Zai Lab Ltd | 1.95% | 79,505 | $2.1M |
| 6 | KNSA | Kiniksa Pharmaceuticals International Plc | 1.92% | 26,155 | $2.0M |
| 7 | PGEN | Precigen Inc | 1.87% | 304,977 | $2.0M |
| 8 | HALO | Halozyme Therapeutics Inc | 1.85% | 19,528 | $2.0M |
| 9 | PTGX | Protagonist Therapeutics Inc | 1.77% | 12,363 | $1.9M |
| 10 | BGNE | BeOne Medicines Ltd | 1.72% | 5,132 | $1.8M |
| 11 | ACAD | ACADIA Pharmaceuticals Inc | 1.72% | 64,350 | $1.8M |
| 12 | GERN | Geron Corp | 1.71% | 1,180,129 | $1.8M |
| 13 | REGN | Regeneron Pharmaceuticals Inc | 1.69% | 2,218 | $1.8M |
| 14 | RYTM | Rhythm Pharmaceuticals Inc | 1.68% | 15,357 | $1.8M |
| 15 | INSM | Insmed Inc | 1.65% | 13,870 | $1.8M |
Page 1 of 4
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | +6.25% | |
| 1W | +7.84% | |
| 1M | +12.23% | |
| 3M | +27.63% | |
| 6M | +30.15% | |
| YTD | +37.93% | |
| 1Y | +64.37% | |
| 3Y | +108.50% | |
| 5Y | +114.03% |
Moving Averages
20-Day MA
$99.23
Above 20-Day MA50-Day MA
$96.55
Above 50-Day MA200-Day MA
$85.56
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$109.90
Current Price
$109.94
52-Week Low
$66.64
$66.64$109.90
Current Yield
—
Annual Dividend
$0.9395
Frequency
0x/year
Last Ex-Date
Dec 20, 2017
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 20, 2017 | $0.0723 | Dec 27, 2017 |
| Dec 20, 2017 | $0.0700 | Dec 27, 2017 |
| Dec 21, 2015 | $0.4000 | Dec 29, 2015 |
| Dec 21, 2015 | $0.3972 | Dec 29, 2015 |
Dividend Payments Over Time
Category Comparison
| Metric | BBP | Healthcare(222 ETFs) | Biotech(41 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.34% | 0.62% | 0.84% |
| AUM | $106.0M | $1.98B | $1.79B |
| Dividend Yield | — | 3.92% | 1.97% |
| Avg Volume | 9.3K | 441.0K | 974.2K |
| Holdings | 198 | 167 | 65 |
| Performance | |||
| 1-Month Return | — | -6.87% | — |
| 6-Month Return | — | -5.23% | — |
| YTD Return | +37.53% | +16.78% | +27.29% |
| 1-Year Return | — | -5.91% | — |
Compare with Another ETF
Search for an ETF to compare with BBP:
FREE DOWNLOAD
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.